Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales’ disease

Kumar, Atul; Sehra, Sri Vatsa; Thirumalesh, M B; Gogia, Varun

doi:10.1007/s00417-011-1890-7

Cited by 19 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…86 Intravitreal bevacizumab injections may be associated with the development of secondary RRD in patients of Eales' disease within 7 days of injection. 87 …”

Section: Adverse Events Following Intravitreal Anti-vegf Injections: mentioning

confidence: 99%

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Falavarjani

Nguyen

2013

Eye

759

505

View full text Add to dashboard Cite

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

show abstract

“…86 Intravitreal bevacizumab injections may be associated with the development of secondary RRD in patients of Eales' disease within 7 days of injection. 87 …”

Section: Adverse Events Following Intravitreal Anti-vegf Injections: mentioning

confidence: 99%

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Falavarjani

Nguyen

2013

Eye

759

505

View full text Add to dashboard Cite

show abstract

“…Solutions are hereby directly injected into the vitreous to achieve the required therapeutic concentration. However, frequent injections are generally required which may result in a higher incidence of pain, risk of infection, endophthalmitis (approximately 0.02% per injection), intraocular inflammation, elevated intraocular pressure (IOP), retinal detachment, and cataract formation . Owing to their controlled release properties NPs may overcome the need for such frequent intravitreal injections.…”

Section: Routes Of Ocular Drug Deliverymentioning

confidence: 99%

Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases

Bisht

Mandal

Jaiswal

et al. 2017

WIREs Nanomed Nanobiotechnol

102

View full text Add to dashboard Cite

Effective drug delivery to the retina still remains a challenge due to ocular elimination mechanisms and complex barriers that selectively limit the entry of drugs into the eye. To overcome these barriers, frequent intravitreal injections are currently used to achieve high drug concentrations in vitreous and retina. However, these repetitive injections may result in several side effects. Recent advancements in the field of nanoparticle-based drug delivery could overcome some of these unmet needs and various preclinical studies conducted to date have demonstrated promising results of nanotherapies in the treatment of retinal diseases. Compared to the majority of commercially available ocular implants, the biodegradable nature of most nanoparticles (NPs) avoids the need for surgical implantation and removal after the release of the payload. In addition, the sustained drug release from NPs over an extended period of time reduces the need for frequent intravitreal injections and the risk of associated side effects. The nanometer size and highly modifiable surface properties make NPs excellent candidates for targeted ocular drug delivery. Studies have shown that nanocarriers enhance the intravitreal half-life and thus bioavailability of a number of drugs including proteins and peptides. In addition, they have shown promising results in delivering genetic material to the retinal tissues by protecting it from possible intravitreal degradation. This review covers the various challenges associated with drug delivery to the posterior segment of the eye, particularly the retina, and highlights the application of nanocarriers to overcome these challenges in context with recent advances in preclinical studies. WIREs Nanomed Nanobiotechnol 2018, 10:e1473. doi: 10.1002/wnan.1473 This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Implantable Materials and Surgical Technologies > Nanomaterials and Implants.

show abstract

“…[123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869] The years between 2007-10, being populated largely by case reports and occasional case series detailing the use of anti-VEGF agents in treating CNVM of other etiology, and retinopathy of prematurity[41] (2007), AMD[3] and adjunct to trabeculectomy[44] (2008). We can see a trend towards randomized case-control studies comparing different anti-VEGF agents, the use of combination treatments in AMD and other diseases since 2011 onwards.…”

Section: Resultsmentioning

confidence: 99%

Changing paradigms of anti-VEGF in the Indian scenario

Shanmugam

2014

Indian J Ophthalmol

View full text Add to dashboard Cite

Anti-vascular endothelial growth factors (VEGF) agents have revolutionized the treatment of retinal diseases. Use of anti-VEGF agents in the Indian Scenario present some unique challenges considering the absence of compounding pharmacies, poor penetrance of health insurance and limited affordability of the citizens of a developing economy. To study the changing paradigms of anti-VEGF use in the Indian scenario, all articles published by Indian authors, data from web-based surveys amongst Indian vitreo-retinal specialists were reviewed. In the paucity of compounding pharmacies in India, fractionation and injection techniques differ from those of developed countries. Frequent anti-VEGF monotherapy offers the best anatomical and visual results, but economics of scale do not allow the same in the Indian scenario, resulting in PRN dosing and combination of anti-VEGF with laser photocoagulation, being the commonly employed treatment protocols.

show abstract

Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales’ disease

Abstract: Intravitreal bevacizumab injections may be associated with the serious complication of secondary RRD in patients of Eales' disease within 7 days of injection.

Cited by 19 publications

References 22 publications

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases

Changing paradigms of anti-VEGF in the Indian scenario

Contact Info

Product

Resources

About